Processa Pharmaceuticals Inc (PCSA) - Total Liabilities
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has total liabilities worth $1.98 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Processa Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Processa Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Processa Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Processa Pharmaceuticals Inc asset portfolio.
Processa Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
tokentus investment AG
MU:14D
|
Germany | €158.49K |
|
RUBIX Resources Ltd
AU:RB6
|
Australia | AU$204.68K |
|
XP Power Ltd
LSE:XPP
|
UK | GBX250.00 Million |
|
Agri-Tech (India) Limited
NSE:AGRITECH
|
India | Rs10.10 Million |
|
Palred Technologies Limited
NSE:PALREDTEC
|
India | Rs753.39 Million |
|
HLT Global Bhd
KLSE:0188
|
Malaysia | RM76.94 Million |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$341.73K |
|
Stenocare AS
CO:STENO
|
Denmark | Dkr3.73 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Processa Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PCSA net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Processa Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Processa Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Processa Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.24 Million | +45.86% |
| 2024-12-31 | $1.53 Million | +92.24% |
| 2023-12-31 | $797.48K | -30.60% |
| 2022-12-31 | $1.15 Million | +17.45% |
| 2021-12-31 | $978.40K | -56.99% |
| 2020-12-31 | $2.27 Million | -20.75% |
| 2019-12-31 | $2.87 Million | -18.30% |
| 2018-12-31 | $3.51 Million | +34.63% |
| 2017-12-31 | $2.61 Million | +25.28% |
| 2016-12-31 | $2.08 Million | 0.00% |
| 2015-12-31 | $2.08 Million | +56.14% |
| 2014-12-31 | $1.33 Million | +5.28% |
| 2013-12-31 | $1.27 Million | -4.13% |
| 2012-12-31 | $1.32 Million | -47.77% |
| 2011-12-31 | $2.53 Million | -- |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more